Evidence map›Paper›PMID 34059760›Full record

ArticleScientific reports2021

A practice of using five-colour chart to guide the control of COVID-19 and resumption of work in Zhejiang Province, China.

Fan He, Xiaopeng Shang, Feng Ling, Zhiping Chen, Tiehong Fu, Junfen Lin, Zhen Wang

Abstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fan He *Zhejiang Provincial Center for Disease Control and Prevention, Zhejiang, China.
Xiaopeng Shang *Zhejiang Provincial Center for Disease Control and Prevention, Zhejiang, China.
Feng LingZhejiang Provincial Center for Disease Control and Prevention, Zhejiang, China.
Zhiping ChenZhejiang Provincial Center for Disease Control and Prevention, Zhejiang, China.
Tiehong FuZhejiang Provincial Health Commission, Zhejiang, China.
Junfen LinZhejiang Provincial Center for Disease Control and Prevention, Zhejiang, China.
Zhen WangZhejiang Provincial Center for Disease Control and Prevention, Zhejiang, China. wangzhen666505@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the outbreak of COVID-19 in December 2019 in Wuhan, Zhejiang has become the province with the largest number of cases. The aim of this article is to present Zhejiang province's experience of establishing an accurate and smart control mechanism for epidemic prevention and control and resumption of work and production using a 'five-colour epidemic chart'. The number of confirmed cases, proportion of local cases, and occurrence of clustered outbreaks were used as evaluation indicators to calculate the county-level epidemic risk and were assigned different weight coefficients; the absence of cases for 3 and 7 consecutive days was used as the adjustment index. When the first chart was published on February 9, there were 1 very-high-risk, 12 high-risk, and 12 low-risk counties. Under the five-colour chart, Zhejiang began to adopt precise measures to prevent and control the epidemic and resume work and production. By February 24, the low-risk counties had expanded to 82, with no high-risk and very-high-risk counties. The epidemic situation in Zhejiang province has been effectively controlled. The experience of epidemic prevention and control in Zhejiang is worthy to be emulated and learned by other countries and regions.

Indexed as

ChinaColorCOVID-19Disease OutbreaksEpidemicsHumansPandemicsQuarantineRisk Assessment

Identifiers

PMID34059760
PMCPMC8167099

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.